Results: Medical Developments International profit grows 327%

The Medical Developments International (ASX: MVP) share price is up today after reporting profit growth of 327%

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price is on the rise today after the company reported its results for the 2019 financial year (FY19) this morning. MVP shares opened at $4.76, but have since jumped to $4.94 at the time of reporting – a rise of 3.78%.

What were MVP's numbers like?

Here is a summary of the numbers that Medical Development put out his morning:

  • Gross revenue up 19.3% (compared to FY18) to $21.38 million
  • Net revenue up 19.6% to $20.88 million
  • Net profit after tax up 327% to $1.04 million
  • Operating expenses grew 8% due to marketing and insurance costs as well as employee share payments
  • Earnings per share up 293% to 1.61 cents
  • Final dividend of 2 cents per share (fully franked), taking total dividend per share for FY19 to 4 cents
  • Net tangible asset backing per share (as of June 30 2019) at 5.6 cents, up from negative 17.9 cents at the end of FY18.

Medical Developments reported that sales of its flagship Penthrox medicine grew 47% overall, with a 32% rise in Australian sales and a 68% rise in UK sales. Penthrox is yet to be approved by the US Food and Drug Administration (FDA) but hopes to gain approval by the 2023 financial year, pending further trials.

Meanwhile, sales of Respiratory Medical Devices grew 62% in the US market, 111% in the Asian market and 9% in the Australian market, but were down 53% in the UK/EU, leading to an overall decline of 5%. The company hopes to reverse its UK/EU declines during FY20.

Outlook for MVP

MVP reiterated its goal to make Penthrox the "mainstream analgesic of choice around the world". Over the coming year, the company expects to complete the rollout of Penthrox in Europe as well as Asian and Middle Eastern markets, whilst progressing with its pending approvals in the US market as well as the Chinese market.

Advancing work on "producing other analgesic and pharmaceutical products using the intellectual property that is our new manufacturing process" remains part of MVP's long-term plans, as well as consolidating and growing Respiratory Device sales in "the USA, Europe and elsewhere".

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »